FDA Seeks to Withdraw Approval of Tavneos Over Alleged Trial Data Manipulation
· GlobeWire Daily Science Desk · Source: arstechnica.com

Image: Ars Technica · Photo source · Resized and letterboxed to 16:9; no AI generation
The U.S. Food and Drug Administration (FDA) is seeking to withdraw its approval of Tavneos, an autoimmune vasculitis medication, following allegations that the original trial data submitted by ChemoCentryx was manipulated. The drug, which was approved in October 2021 and subsequently acquired by Amgen, is used to help patients reduce their reliance on steroids. However, the FDA argues the drug now lacks substantial evidence of efficacy and has been linked to reports of serious liver injury.
Regulatory and International Actions
- U.S. Action: The FDA issued a letter proposing market withdrawal in April 2026.
- International Status: The European Union and the United Kingdom have moved to remove the product from their markets, and a related clinical trial paper was retracted by the *New England Journal of Medicine*.
- Legal Proceedings: A court hearing is expected to address a proposed $69 million settlement regarding an investor lawsuit tied to the data allegations.
Arguments From Amgen and Supporters
Amgen has defended the medication, submitting a 104-page document arguing that the totality of evidence supports keeping Tavneos available. The company maintains that no clinical data were fundamentally altered and that re-adjudication corrected minor errors. Some patients and independent researchers also advocate for the drug's continued availability, citing its potential to reduce steroid dependency and real-world safety data indicating manageable risks when monitored properly.
Verification and Practical Implications
Patients and physicians currently navigating treatment decisions face an ongoing period of uncertainty as regulatory and legal battles continue. Official updates and announcements regarding the regulatory status of Tavneos can be verified directly through the FDA's official communications and announcements pages.
AI-assisted reporting; source claims are attributed and have not been independently verified.



